# Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

> **NCT00471146** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 630 (actual)

## Conditions studied

- Carcinoma, Pancreatic Ductal

## Interventions

- **DRUG:** AG-013736
- **DRUG:** Gemcitabine
- **DRUG:** Gemcitabine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00471146
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-01
- **Final completion:** 2010-11
- **Target enrollment:** 630 (ACTUAL)
- **Last updated:** 2012-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00471146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00471146, "Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00471146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*